Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome.
Hornig, M, Gottschalk, G, Peterson, D L et al. · Molecular psychiatry · 2016 · DOI
Quick Summary
Researchers examined fluid from around the spine (cerebrospinal fluid) in ME/CFS patients and compared it to healthy people and those with multiple sclerosis. They found that ME/CFS patients had unusual patterns of immune proteins called cytokines in this fluid, suggesting their immune system in the brain and spinal cord is activated differently. The most notable finding was higher levels of a protein called eotaxin, which typically helps recruit immune cells involved in allergic responses.
Why It Matters
This study provides objective biological evidence of central nervous system immune activation in ME/CFS, supporting the hypothesis that the condition involves measurable immune dysfunction rather than being purely psychological. Identifying specific immune signatures in cerebrospinal fluid could eventually lead to diagnostic biomarkers and targeted treatments for this poorly understood disease.
Observed Findings
Elevated CCL11 (eotaxin) in ME/CFS cerebrospinal fluid compared to controls
Disturbed interleukin-1 signaling with inverse relationship between IL-1RA and CSF1/CSF2/IL-17F
Markedly different cytokine network patterns in ME/CFS versus both MS and healthy controls
Shift toward T helper type-2 immune response pattern in ME/CFS cases
Majority of the 51 analytes showed group-specific differences between cohorts
Inferred Conclusions
Central nervous system immune activation occurs in ME/CFS with a distinctive cytokine signature
IL-1 signaling is specifically disrupted in ME/CFS, distinct from effects on IL-1α or IL-1β
Immune dysregulation in ME/CFS involves a shift toward allergic and autoimmune-associated T helper type-2 patterns
The cerebrospinal fluid immune profile in ME/CFS is distinct from that observed in MS
Remaining Questions
Do these cytokine abnormalities persist over time, and do they correlate with symptom severity or disease progression?
Are these immune changes primary to ME/CFS pathogenesis or secondary consequences of the disease?
What This Study Does Not Prove
This study does not establish whether the observed immune abnormalities cause ME/CFS symptoms or are a consequence of the disease. It cannot prove causation or determine whether these cytokine patterns would be useful as clinical diagnostic tests without validation in larger populations. The findings are correlational and require replication and longitudinal studies to understand their prognostic significance.